As per the research report, the size of the Asia Pacific Viral Inactivation Market is valued at USD 95.26 million in 2020 and estimated to be growing at a CAGR of 13.6%, to reach USD 180.22 million by 2025 during the forecast period 2020-2025.
Viral Inactivation can be defined as the procedure by which viral cells are killed or made inactive. The purpose of this method is to increase the safety and to avert contamination of products by viruses. Viruses can be present in the final product but only in an inactive form. All the methods are performed primarily in blood plasma and food industries in order to protect the products from viruses.
There are many methods in which viral inactivation is achieved. Some of them are dry heating, pasteurization, irradiation by UV rays, solvent/detergent usage and lowering of pH among others. Pasteurization is a useful method only when the proteins which are to be protected are more thermally resistant than viruses. Viral Inactivation by solvents and detergents is the most used method in the blood plasma industry. It is effective only when viruses are encapsulated in lipid molecules. The detergents/solvents interact with the lipid layers and make the viruses ineffective as they cannot survive without lipid molecules. UV radiations kill the viruses by creating nucleic acid dimers, thus affecting their life cycle and reproduction processes. Lowering pH is effective only when the molecules in the product are more resistant than viruses.
The driving factors of the Asia-Pacific Viral Inactivation market are rising support of the government in biotechnology and pharmaceuticals sectors, increasing support of the government in biotechnology and pharmaceutical sectors, attention of research and development industries in life sciences, the launch of new drugs and rising incidence of chronic diseases and among others. Some of the setbacks of this market are the presence of strong consolidation and fewer skilled workers.
This research report segmented and sub-segmented into the following categories:
Asia-Pacific the globally the fastest-growing region. Factors such as rising support of the government, increasing incidence of chronic disease, a huge number of patients and the launch of new drugs is expected to be the driving factors of growth for this market in the forecast period.
The Top companies leading in the APAC Viral Inactivation Market profiled in the report are Clean Cells, Charles River Laboratories International Inc, Danaher Corporation, Merck KGaA, Parker Hannifin, Red Source Technologies, Sartorius AG, SGS S.A, Texcell Inc, Viral Inactivated Plasma Systems SA, and WuXi Pharma Tech Inc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Method
5.1.1 Solvent/Detergent Method
5.1.2 Pasteurization
5.1.3 UV Radiation
5.1.4 Microwave Heating
5.1.5 High-Energy Light
5.1.6 Y-o-Y Growth Analysis, By Method
5.1.7 Market Attractiveness Analysis, By Method
5.1.8 Market Share Analysis, By Method
5.2 Product
5.2.1 Kits and Reagents
5.2.2 Services
5.2.3 Accesories
5.2.4 Viral Inactivation Systems
5.2.5 Y-o-Y Growth Analysis, By Product
5.2.6 Market Attractiveness Analysis, By Product
5.2.7 Market Share Analysis, By Product
5.3 Application
5.3.1 Vaccines and Therapeutics
5.3.2 Stem Cell Products
5.3.3 Cell Culture
5.3.4 Gene Therapy
5.3.5 Blood & Blood Products
5.3.6 Y-o-Y Growth Analysis, By Application
5.3.7 Market Attractiveness Analysis, By Application
5.3.8 Market Share Analysis, By Application
5.4 End User
5.4.1 Pharmaceutical and Biotechnology Companies
5.4.2 Contract Research Organizations
5.4.3 Academic Research Institutes
5.4.4 Other End Users
5.4.5 Y-o-Y Growth Analysis, By End User
5.4.6 Market Attractiveness Analysis, By End User
5.4.7 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Method
6.1.3.2 By Product
6.1.3.3 By Application
6.1.3.4 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Method
6.1.4.2 By Product
6.1.4.3 By Application
6.1.4.4 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Method
6.1.5.2 By Product
6.1.5.3 By Application
6.1.5.4 By End User
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Clean Cells
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Charles River Laboratories International Inc.
8.3 Danaher Corporation
8.4 Merck KGaA
8.5 Parker Hannifin
8.6 Red Source Technologies
8.7 Sartorius AG
8.8 SGS S.A
8.9 Texcell Inc
8.10 Viral Inactivated Plasma Systems SA
8.11 WuXi Pharma Tech Inc.
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
